Thomas M. Tu, MD has been appointed Chief Medical Officer of Inari Medical.
Dr. Tu is a pioneer in definitive catheter-based treatment of pulmonary embolism (PE). He was the lead author in the publication of the FLARE trial that resulted in FDA clearance of the FlowTriever device for PE. “I am excited to join Inari Medical, which is poised to revolutionize treatment of pulmonary embolism and deep venous thrombosis,” said Dr. Tu. Prior to Inari, Dr. Tu was in practice in Louisville, Kentucky for 16 years. He served as Director of the Cardiac Catheterization Laboratory at Baptist Health Louisville, where he led the TAVR, PE, and CTO programs.
Dr. Tu is formerly the chairman of the Emerging Leader Mentorship program, a joint venture among SCAI, ACC, and CRF. He is also the former chairman of the SCAI-PAC. He is currently interested in new device development and healthcare transformation.
“Tom brings deep clinical and advocacy experience to Inari Medical,” said Bill Hoffman, CEO of Inari. “As we continue to execute our plan to produce and publish clinical data, expand our portfolio of venous disease treatment solutions, and train many more physician users, Tom’s expertise and perspective will be invaluable.”
Dr. Tu is a graduate of Harvard Medical School. He completed his medical and cardiology training at Massachusetts General Hospital and Beth Israel Deaconess Medical Center. He is board-certified in cardiology, interventional cardiology, and is fellowship-trained in peripheral vascular intervention.